Journal of Thoracic Oncology
The page or action you requested has resulted in an error. Please go back to the previous page by using your browser’s Back button, or visit the Home Page.
Related Articles
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Amivantamab is an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity. We assessed amivantamab’s safety and efficacy in participants with advanced non-small…
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
Precision oncology has transformed the management of non-small cell lung cancer (NSCLC) by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such…
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Amivantamab is an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity. We assessed amivantamab’s safety and efficacy in participants with advanced non-small…
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Nature Reviews Clinical Oncology – Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of…
Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention
Nature Reviews Clinical Oncology – The composition of the gut microbiota has been implicated as a key determinant of not only the clinical efficacy but…
Targeting the glioblastoma resection margin with locoregional nanotechnologies
Nature Reviews Clinical Oncology – Patients with resectable glioblastoma undergo upfront surgery followed by adjuvant radiotherapy plus chemotherapy. This approach implies a period of approximately…
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
Precision oncology has transformed the management of non-small cell lung cancer (NSCLC) by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such…
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC
Nature Reviews Clinical Oncology – Promising results with zongertinib in advanced-stage HER2-mutant NSCLC
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer
Nature Reviews Clinical Oncology – Anal squamous cell carcinoma (ASCC) is a rare malignancy, albeit with an increasing prevalence in most economically developed countries. Despite…
Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multi-center trial
Uncommon EGFR mutations comprise 10-20% of all EGFR mutations in non-small cell lung cancer (NSCLC) and generally show reduced responsiveness to EGFR tyrosine kinase inhibitors…
